506 related articles for article (PubMed ID: 20183526)
21. Candidate genetic modifiers of individual susceptibility to renal cell carcinoma: a study of polymorphic human xenobiotic-metabolizing enzymes.
Longuemaux S; Deloménie C; Gallou C; Méjean A; Vincent-Viry M; Bouvier R; Droz D; Krishnamoorthy R; Galteau MM; Junien C; Béroud C; Dupret JM
Cancer Res; 1999 Jun; 59(12):2903-8. PubMed ID: 10383153
[TBL] [Abstract][Full Text] [Related]
22. Cytochrome P450 2D6 phenotyping in an elderly population with dementia and response to galantamine in dementia: a pilot study.
Clarke JA; Cutler M; Gong I; Schwarz UI; Freeman D; Dasgupta M
Am J Geriatr Pharmacother; 2011 Aug; 9(4):224-33. PubMed ID: 21803659
[TBL] [Abstract][Full Text] [Related]
23. The influence of genetic polymorphisms on population variability in six xenobiotic-metabolizing enzymes.
Ginsberg G; Smolenski S; Neafsey P; Hattis D; Walker K; Guyton KZ; Johns DO; Sonawane B
J Toxicol Environ Health B Crit Rev; 2009; 12(5-6):307-33. PubMed ID: 20183525
[TBL] [Abstract][Full Text] [Related]
24. Polymorphisms and phenotypic analysis of cytochrome P450 2D6 in the Tibetan population.
Jin TB; Ma LF; Zhang JY; Yuan DY; Sun Q; Zong TY; Geng TT; Cui YL; Kang LL; Chen C
Gene; 2013 Sep; 527(1):360-5. PubMed ID: 23644254
[TBL] [Abstract][Full Text] [Related]
25. Antidepressant treatment and altered CYP2D6 activity: are pharmacokinetic variations clinically relevant?
D'Empaire I; Guico-Pabia CJ; Preskorn SH
J Psychiatr Pract; 2011 Sep; 17(5):330-9. PubMed ID: 21926528
[TBL] [Abstract][Full Text] [Related]
26. Inter-individual variability of in vivo CYP2D6 activity in different genotypes.
Chiba K; Kato M; Ito T; Suwa T; Sugiyama Y
Drug Metab Pharmacokinet; 2012; 27(4):405-13. PubMed ID: 22277677
[TBL] [Abstract][Full Text] [Related]
27. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences.
Sachse C; Brockmöller J; Bauer S; Roots I
Am J Hum Genet; 1997 Feb; 60(2):284-95. PubMed ID: 9012401
[TBL] [Abstract][Full Text] [Related]
28. Cytochrome P450 2D6 phenoconversion is common in patients being treated for depression: implications for personalized medicine.
Preskorn SH; Kane CP; Lobello K; Nichols AI; Fayyad R; Buckley G; Focht K; Guico-Pabia CJ
J Clin Psychiatry; 2013 Jun; 74(6):614-21. PubMed ID: 23541126
[TBL] [Abstract][Full Text] [Related]
29. CYP2D6 polymorphism: implications for antipsychotic drug response, schizophrenia and personality traits.
Dorado P; Peñas-Lledó EM; Llerena A
Pharmacogenomics; 2007 Nov; 8(11):1597-608. PubMed ID: 18034624
[TBL] [Abstract][Full Text] [Related]
30. Recent examples on the clinical relevance of the CYP2D6 polymorphism and endogenous functionality of CYP2D6.
Haertter S
Drug Metabol Drug Interact; 2013; 28(4):209-16. PubMed ID: 24088607
[TBL] [Abstract][Full Text] [Related]
31. Molecular mechanisms of genetic polymorphisms of drug metabolism.
Meyer UA; Zanger UM
Annu Rev Pharmacol Toxicol; 1997; 37():269-96. PubMed ID: 9131254
[TBL] [Abstract][Full Text] [Related]
32. Cytochrome P
Dhuya M; Pal MM; Hazra A; Chatterjee S; Gogtay N
Indian J Pharmacol; 2020; 52(3):189-195. PubMed ID: 32874001
[TBL] [Abstract][Full Text] [Related]
33. Polymorphic cytochrome P450 2D6: humanized mouse model and endogenous substrates.
Yu AM; Idle JR; Gonzalez FJ
Drug Metab Rev; 2004 May; 36(2):243-77. PubMed ID: 15237854
[TBL] [Abstract][Full Text] [Related]
34. Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population.
Griese EU; Zanger UM; Brudermanns U; Gaedigk A; Mikus G; Mörike K; Stüven T; Eichelbaum M
Pharmacogenetics; 1998 Feb; 8(1):15-26. PubMed ID: 9511177
[TBL] [Abstract][Full Text] [Related]
35. Genetic polymorphism in CYP2E1: Population distribution of CYP2E1 activity.
Neafsey P; Ginsberg G; Hattis D; Johns DO; Guyton KZ; Sonawane B
J Toxicol Environ Health B Crit Rev; 2009; 12(5-6):362-88. PubMed ID: 20183527
[TBL] [Abstract][Full Text] [Related]
36. Genetic polymorphism of cytochrome P450 2D6 determines oestrogen receptor activity of the major infertility drug clomiphene via its active metabolites.
Mürdter TE; Kerb R; Turpeinen M; Schroth W; Ganchev B; Böhmer GM; Igel S; Schaeffeler E; Zanger U; Brauch H; Schwab M
Hum Mol Genet; 2012 Mar; 21(5):1145-54. PubMed ID: 22108178
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of probe drugs and pharmacokinetic metrics for CYP2D6 phenotyping.
Frank D; Jaehde U; Fuhr U
Eur J Clin Pharmacol; 2007 Apr; 63(4):321-33. PubMed ID: 17273835
[TBL] [Abstract][Full Text] [Related]
38. Unique CYP2D6 activity distribution and genotype-phenotype discordance in black Americans.
Gaedigk A; Bradford LD; Marcucci KA; Leeder JS
Clin Pharmacol Ther; 2002 Jul; 72(1):76-89. PubMed ID: 12152006
[TBL] [Abstract][Full Text] [Related]
39. CYP2D6 genotype information to guide pimozide treatment in adult and pediatric patients: basis for the U.S. Food and Drug Administration's new dosing recommendations.
Rogers HL; Bhattaram A; Zineh I; Gobburu J; Mathis M; Laughren TP; Pacanowski M
J Clin Psychiatry; 2012 Sep; 73(9):1187-90. PubMed ID: 23059146
[TBL] [Abstract][Full Text] [Related]
40. Effectiveness of a high-throughput genetic analysis in the identification of responders/non-responders to CYP2D6-metabolized drugs.
Savino M; Seripa D; Gallo AP; Garrubba M; D'Onofrio G; Bizzarro A; Paroni G; Paris F; Mecocci P; Masullo C; Pilotto A; Santini SA
Clin Lab; 2011; 57(11-12):887-93. PubMed ID: 22239018
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]